Cravacin Deucravacitinib Fluvoxamine Maleate
MinorIn clinical trials, Deucravacitinib did not show any clinically significant change in how the body handles it when taken together with fluvoxamine (a CYP1A2 inhibitor). The same was true for cyclosporine (a dual Pgp/BCRP inhibitor), ritonavir (a CYP1A2 inducer), diflunisal (a UGT 1A9 inhibitor), pyrimethamine (an OCT1 inhibitor), famotidine (an H2 receptor antagonist) and rabeprazole (a proton pump inhibitor).
Little or no effect is expected. You usually do not need to change anything, but still tell your doctor or pharmacist about every medicine you take.